Published in Ann Intern Med on February 01, 1968
Specificity of opsonic antibodies to enhance phagocytosis of Pseudomonas aeruginosa by human alveolar macrophages. J Clin Invest (1975) 2.04
Microscopic characterization of rabbit lung damage produced by Pseudomonas aeruginosa proteases. Infect Immun (1979) 1.75
Development of cellular and humoral immunity in the respiratory tract of rabbits to Pseudomonas lipopolysaccharide. J Clin Invest (1974) 1.08
Production and characterization of monoclonal antibodies to exotoxin A from Pseudomonas aeruginosa. Infect Immun (1984) 0.99
Antibody response to Pseudomonas aeruginosa exoproducts in cancer patients. J Clin Microbiol (1982) 0.92
Unilateral pulmonary oedema and Pseudomonas pneumonia. Postgrad Med J (1980) 0.87
Prevalence and risk factors for chronic co-infection in pulmonary Mycobacterium avium complex disease. BMJ Open Respir Res (2014) 0.87
Tobramycin in bronchial secretions. Antimicrob Agents Chemother (1973) 0.84
Infectious disease emergencies. Part III: Patients presenting with respiratory distress syndromes. West J Med (1976) 0.77
Thin-section CT findings in Pseudomonas aeruginosa pulmonary infection. Br J Radiol (2012) 0.77
Bacterial colonization and clinical superinfection of the respiratory tract complicating antibiotic treatment of pneumonia. J Infect Dis (1969) 2.80
Virus myocardiopathy. Prog Med Virol (1973) 2.73
Residual pathologic changes following murine coxsackie A and B myocarditis. Am J Pathol (1969) 2.47
Current problems in the treatment of infective endocarditis due to Pseudomonas aeruginosa. Rev Infect Dis (1983) 1.80
Characteristics of pneumonias caused by Escherichia coli. N Engl J Med (1967) 1.68
Incubation of swab materials with herpes simplex virus. J Infect Dis (1980) 1.58
Coxsackievirus myocarditis--with special reference to acute and chronic effects. Prog Cardiovasc Dis (1985) 1.57
Cephalexin and cephaloglycin activity in vitro and absorption and urinary excretion of single oral doses in normal young adults. Appl Microbiol (1968) 1.56
Augmentation of the virulence of murine coxsackie-virus B-3 myocardiopathy by exercise. J Exp Med (1970) 1.54
Simultaneous serum and CSF antibodies in herpes simplex virus encephalitis. JAMA (1978) 1.48
The clinical spectrum of Mycoplasma pneumoniae infections. Med Clin North Am (1978) 1.46
Editorial response: microbial persistence and idiopathic dilated cardiomyopathy. Clin Infect Dis (1999) 1.45
Bacteroides pneumonias. Characteristics of cases with empyema. Ann Intern Med (1968) 1.26
Differential sensitivity of herpes simplex virus types 1 and 2 to human interferon: antiviral effects of interferon plus 9-beta-D-arabinofuranosyladenine. J Infect Dis (1976) 1.21
Plasmapheresis for meningococcemia with disseminated intravascular coagulation. N Engl J Med (1979) 1.19
Herpesvirus hominis encephalitis in Michigan. Report of thirteen cases, including six treated with idoxuridine. N Engl J Med (1970) 1.18
Pneumonias caused by gram negative bacilli. Medicine (Baltimore) (1966) 1.18
Coxsackievirus myocardiopathy. J Infect Dis (1969) 1.17
Passive hemagglutinating antibodies in cerebrospinal fluids in herpesvirus hominis encephalitis. 1. Proc Soc Exp Biol Med (1972) 1.16
Xeroradiographic, bacteriologic, and pathologic studies in experimental staphylococcus osteomyelitis. Proc Soc Exp Biol Med (1977) 1.16
Treatment of patients with pseudomonas endocarditis with high dose aminoglycoside and carbenicillin therapy. Medicine (Baltimore) (1978) 1.16
Hemophilus influenzae bronchopneumonia in adults. Arch Intern Med (1968) 1.14
Randomised, controlled trial of the comparative efficacy, auditory toxicity, and nephrotoxicity of tobramycin and netilmicin. Lancet (1983) 1.14
Idoxuridine in herpes simplex virus (type 1) encephalitis. Experience with 29 cases in Michigan, 1966 to 1971. Ann Intern Med (1973) 1.12
An experimental approach to virus myocarditis. Prog Med Virol (1965) 1.09
A new continuing fatigue syndrome following mild viral illness. A proscription to exercise. Chest (1988) 1.08
Microbiologic assays and neurological toxicity during use of adenine arabinoside in humans. J Infect Dis (1976) 1.07
Theophylline-induced seizures: clinical and pathophysiologic aspects. West J Med (1983) 1.05
Modified polyriboinosinic-polyribocytidylic acid complex: sustained interferonemia and its physiological associates in humans. Infect Immun (1979) 1.05
Comparison of the effects of arabinosyladenine, arabinosylhypoxanthine, and arabinosyladenine 5'-monophosphate against herpes simplex virus, varicella-zoster virus, and cytomegalovirus with their effects on cellular deoxyribonucleic acid synthesis. Antimicrob Agents Chemother (1981) 1.04
Mycotic aneurysm and endocarditis. Two uncommon complications of salmonella infection in the same patient. Am J Cardiol (1966) 1.04
The classic bacterial pneumonias. Dis Mon (1975) 1.03
Complement-requiring neutralizing antibodies in Herpesvirus hominis encephalitis. J Immunol (1970) 1.02
Enterovirus hemagglutination: inhibition by several enzymes and sugars. J Immunol (1965) 1.02
A mouse model of dilated-type cardiomyopathy due to coxsackievirus B3. J Infect Dis (1981) 1.01
Synergy of 9-beta-D-arabinofuranosyladenine and human interferon against Herpes simplex virus, type 1. J Infect Dis (1974) 1.00
Herpesvirus hominis encephalitis. Neurological manifestations and use of idoxuridine. Arch Neurol (1970) 1.00
Serologic responses to herpes simplex virus in rabbits: complement-requiring neutralizing, conventional neutralizing, and passive hemagglutinating antibodies. J Infect Dis (1974) 0.99
Virus myopericarditis. Ann Intern Med (1968) 0.99
Legionnaires' disease. Report of a case with unusual manifestations. Arch Intern Med (1980) 0.98
Pseudomonas cepacia peritonitis associated with contamination of automatic peritoneal dialysis machines. Ann Intern Med (1982) 0.98
Non-traumatic gram-negative bacillary meningitis in the Detroit Medical Center, 1964-1974; (with special mention of cases due to Escherichia coli). Medicine (Baltimore) (1978) 0.97
Synergy between carbenicillin and an aminoglycoside (gentamicin or tobramycin) against Pseudomonas aeruginosa isolated from patients with endocarditis and sensitivity of isolates to normal human serum. J Infect Dis (1979) 0.97
Gentamicin in treatment of primary Gram-negative pneumonias. Am J Med Sci (1970) 0.96
Age-dependent pathogenicity of group B coxsackieviruses in Swiss-Webster mice: infectivity for myocardium and pancreas. J Infect Dis (1980) 0.96
Cellular interactions of several enteroviruses and a reovirus after treatment with sodium borohydride or carbohydrases. Virology (1968) 0.96
Some previously unrecognized features of herpes simplex virus encephalitis. Neurology (1978) 0.94
Endocarditis caused by Moraxella nonliquefaciens. South Med J (1979) 0.93
Characteristics and sequelae of paregoric abuse. Ann Intern Med (1966) 0.93
Enterovirus hemagglutination: inhibition by aldoses and a possible mechanism. J Immunol (1966) 0.92
Antiherpesvirus activity in human sera and urines after administration of adenine arabinoside: in vitro and in vivo synergy of adenine arabinoside and arabinosylhypoxanthine in combination. J Clin Invest (1978) 0.92
Granulocytopenia associated with carbenicillin. Five episodes in two patients. Am J Med (1973) 0.90
Agranulocytosis associated with chronic oral administration of cloxacillin for suppression of staphylococcal osteomyelitis. Am J Hematol (1982) 0.90
Renal and auditory toxicity of high-dose, prolonged therapy with gentamicin and tobramycin in pseudomonas endocarditis. J Infect Dis (1984) 0.90
Role of bacterial infection in exacerbation of multiple sclerosis. Am J Phys Med Rehabil (1996) 0.89
Immunoassay with cytomegalovirus early antigens from gene products p52 and CM2 (UL44 and UL57) detects active infection in patients with chronic fatigue syndrome. J Clin Pathol (2007) 0.89
Gram-negative pneumonia in hospitalized patients. Postgrad Med (1975) 0.89
Pseudomonas endocarditis: hemagglutinating antibodies to Fisher-Devlin-Gnabasik immunotypes in sera. J Lab Clin Med (1974) 0.89
Congenital infections with reovirus. J Exp Med (1966) 0.89
Antiviral activity of an adenosine deaminase inhibitor: decreased replication of herpes simplex virus. J Infect Dis (1975) 0.89
The gram-negative bacillary pneumonias. Dis Mon (1980) 0.88
Pyrogenic reactions after inadvertent infusion of endotoxin during cardiac catheterizations. Ann Intern Med (1980) 0.87
Eczema herpeticum: presenting as hand, foot and mouth syndrome. Mich Med (1972) 0.87
Gram-negative bacillary pneumonia. J Infect Dis (1971) 0.86
Coxsackievirus B4 myocarditis in mice: valvular changes in virus-infected and control animals. J Infect Dis (1978) 0.86
Effect of periodate oxidation on hemagglutinating and antibody-producing capacities of certain enteroviruses and reoviruses. Proc Natl Acad Sci U S A (1966) 0.86
A mouse model of transmural myocardial necrosis due to coxsackievirus B4: observations over 12 months. Intervirology (1982) 0.86
Guide to immunization against mumps. J Infect Dis (1970) 0.86
Studies of in vitro synergy between several beta-lactam and aminoglycoside antibiotics against endocarditis strains of Pseudomonas aeruginosa. J Infect (1984) 0.86
Ventricular aneurysms complicating coxsackievirus group B, types 1 and 4 murine myocarditis. Circulation (1979) 0.85
Gentamicin/amikacin-resistant gram-negative bacilli at Detroit General Hospital, 1975-1976. Am J Med (1977) 0.85
Possible pseudoresistance of Streptococcus pneumoniae to penicillin G in a patient with a mixed pneumococcus-Staphylococcus aureus pneumonia. Am J Med Sci (1984) 0.84
Epidemiologic studies on influenza in familial and general population groups, 1951-1956. V. Effectiveness of adjuvant vaccines. Am J Epidemiol (1969) 0.84
Interferon in biopsy and autopsy specimens of brain. Its presence in herpes simplex virus encephalitis. Arch Neurol (1980) 0.83
Diminution in the size of the thymus in mice during forced swimming. J Infect Dis (1981) 0.83
Interferon and neutralizing antibody in sera of exercised mice with coxsackievirus B-3 myocarditis. Proc Soc Exp Biol Med (1976) 0.83
Herpetic whitlow: a manifestation of primary infection with herpes simplex virus type 1 or type 2. J Infect Dis (1978) 0.83
Ultrasound imaging of residual limbs: new use for an old technique. Arch Phys Med Rehabil (1989) 0.82
Inhibitory and lethal concentrations of 9-beta-D-arabinofuranosyladenine and its hypoxanthine-derivative versus herpes simplex virus, type 1. J Lab Clin Med (1977) 0.82
Assessment of cytosine arabinoside as an antiviral agent in humans. Antimicrob Agents Chemother (1974) 0.82
Concentrations of idoxuridine in serum, urine, and cerebrospinal fluid of patients with suspected diagnoses of Herpesvirus hominis encephalitis. J Clin Invest (1972) 0.82
Differentiation of several isolates of Peptococcus magnus by counterimmunoelectrophoresis. Infect Immun (1977) 0.82
Modified polyriboinosinic-polyribocytidylic acid complex: induction of serum interferon, fever, and hypotension in rabbits. Antimicrob Agents Chemother (1980) 0.82
Secondary pulmonary infections following antibiotic therapy for primary bacterial pneumonia. Antimicrob Agents Chemother (Bethesda) (1968) 0.82
Epidemiologic aspects of postoperative sepsis in a urologic practice (with a note concerning antibacterial prophylaxis). J Urol (1971) 0.81
An estimate of the course of herpes simplex virus encephalitis. Scand J Infect Dis (1976) 0.81
A small, randomized, placebo-controlled trial of the use of antiviral therapy for patients with chronic fatigue syndrome. Clin Infect Dis (2001) 0.81
Characteristics of pneumonias caused by Bacillus proteus. Ann Intern Med (1968) 0.80
Characteristics of bacterial endocarditis in heroin addicts in Detroit. Am J Med Sci (1976) 0.80
Absence of idoxuridine and persistence of herpes simplex virus in brains of patients being treated for encephalitis. Proc Soc Exp Biol Med (1975) 0.80
Coxsackievirus B3-positive mononuclear leukocytes in peripheral blood of Swiss and athymic mice during infection. Proc Soc Exp Biol Med (1980) 0.79